Close Menu

SAN ANTONIO — New data has reiterated that adding pertuzumab (Genentech's Perjeta) to the legacy HER2 inhibitor trastuzumab (Herceptin), along with chemotherapy in the adjuvant setting, improves breast cancer outcomes for patients with HER-2-positive early-stage breast cancer over the previous standard of just trastuzumab and chemo.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.